Form 4: C4 Therapeutics Chief Scientific Officer Reports Stock and Option Transactions

Paige Mahaney, Chief Scientific Officer of C4 Therapeutics, reports acquisition of restricted stock units and stock options, along with disposal of common stock.

Summary

• On February 14, 2025, Paige Mahaney, the Chief Scientific Officer of C4 Therapeutics, reported transactions involving the company's securities.
• Mahaney acquired 28,200 shares of common stock through restricted stock units (RSUs) at a price of $0.
• These RSUs vest in four equal annual installments starting February 14, 2026.
• Mahaney also acquired options to purchase 42,400 shares of common stock at an exercise price of $3.18.
• These options vest in forty-eight equal monthly installments beginning March 14, 2025, and expire on February 13, 2035.
• Additionally, Mahaney disposed of 105,000 shares of common stock.

Sentiment

Score: 5

Explanation: Neutral sentiment. The acquisition of options is a positive sign, but the disposal of shares introduces uncertainty. The overall impact is likely to be moderate.

Positives

• The acquisition of stock options by a key executive could signal confidence in the company's future performance.

Negatives

• The disposal of 105,000 shares of common stock by the Chief Scientific Officer could be interpreted negatively by investors.

Risks

• Executive stock disposals can sometimes indicate a lack of confidence in the company's short-term prospects, although there may be other personal financial reasons for the sale.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge executive sentiment and potential future stock performance.

Stakeholder Impact

• Shareholders may react to the reported transactions, potentially influencing the stock price.

Key Dates